Effects of a Single Oral Dose of Milrinone on Left Ventricular Systolic Performance

  • F. Piscione
  • B. E. Jaski
  • P. W. Serruys
Conference paper


The introduction of the cardiac bipyridines into the pharmacotherapy of congestive heart failure marked the beginning of innovative research in this area of cardiovascular pharmacology [1, 5, 6]. The forerunner of this new group of compounds was amrinone, which has been proved effective both intravenously [10] and orally [11] in treating congestive heart failure. The limitation of this drug is the high incidence, after long-term oral therapy, of gastrointestinal side effects, thrombocytopenia, and fever [11, 18].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Alousi AA, Farah AE (1980) Amrinone a new oral and parenteral cardiotonic agent. Trends Pharmacol Sci 1: 143–146CrossRefGoogle Scholar
  2. 2.
    Alousi AA, Canter JM, Montenaro MJ, Fort DJ, Ferrari RA (1983a) Cardiotonic activity of Milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 5: 792–803PubMedCrossRefGoogle Scholar
  3. 3.
    Alousi AA, Stankus GP, Stuart JC, Walton LH (1983b) Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bypiridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 5: 804–811PubMedCrossRefGoogle Scholar
  4. 4.
    Baim DS, McDowell AV, Cherniler J, Monard E, Parker JA, Edelwon J, Braunwald E, Grossmann W (1983) Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N Engl J Med 309: 748–756PubMedCrossRefGoogle Scholar
  5. 5.
    Benotti JR, Grossman W, Braunwald E, Davalos DD, Alousi AA (1978) Hemodynamic assessment of amrinone. N Engl J Med 299: 1373–1377PubMedCrossRefGoogle Scholar
  6. 6.
    Farah AE, Alousi AA (1978) New cardiotonic agents: a search for a digitalis substitute. Life Sci 22: 1139–1148PubMedCrossRefGoogle Scholar
  7. 7.
    Hammermeister KE, Brooks RC, Warbasse JR (1974) The rate of change of left ventricular volume in man. I. Validation and peak systolic ejection rate in health and disease. Circulation 49: 729–738PubMedGoogle Scholar
  8. 8.
    Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS (1985) Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest 75: 643–649, 1985.PubMedCrossRefGoogle Scholar
  9. 9.
    Kubo SH, Cody RJ, Chatterjee K, Simonton C, Rutman H, Leonard D (1985) Acute dose range study of milrinone in congestive heart failure. Am J Cardiol 55: 726–730PubMedCrossRefGoogle Scholar
  10. 10.
    Le Jemtel TH, Keung E, Sonnenblick EH, Ribner HS, Matsumoto M, Davis R, Schwartz W, Alousi AA, Davalos DD (1979) Amrinone: a new nonglycosidic, nonadrenergic cardiotonic agent effective in the treatment of intractable myocardial failure in men. Circulation 59: 1098–1104Google Scholar
  11. 11.
    Le Jemtel TH, Keung E, Ribner HS, Davis R, Wexler J, Blaufox M, Sonnenblick E (1980) Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. Am J Cardiol 45: 123–128CrossRefGoogle Scholar
  12. 12.
    Levine HJ, Neill WA, Wagmann RJ (1962) The effects of exercise on mean left ventricular ejection rate in men. J Clin Invest 41: 1050PubMedCrossRefGoogle Scholar
  13. 13.
    Mahler F, Yoran C, Ross J Jr (1974) Inotropic effect of tachycardia and post-stimulation potentiation in the conscious dog. Am J Physiol 227: 569–575PubMedGoogle Scholar
  14. 14.
    Mahler F, Ross J jr, O’Rourke RA, Covell JW (1975) Effects of changes in preload, afterload and inotropic state on ejection and isovolumic phase measures of contractility in the conscious dog. Am J Cardiol 35: 626–634PubMedCrossRefGoogle Scholar
  15. 15.
    Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, Le Jemtel TH (1983) Sustained hemodynamic and clinical effects of a new cardiotonic agent, Win 47203, in patients with severe congestive heart failure. Circulation 67: 1065–1070PubMedCrossRefGoogle Scholar
  16. 16.
    Sarnoff SJ, Mitchell JH (1962) The control of the function of the heart. In: Hamilton WF, Dow P (eds) Handbook of Physiology, sec 2, vol 1. American Physiological Society, Washington D.C.Google Scholar
  17. 17.
    Scott Monrad E, McKay RG, Baim DS, Colucci WS, Fifer MA, Heller GV, Royal HD, Grossmann W (1984) Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 70: 1030–1037CrossRefGoogle Scholar
  18. 18.
    Silverman BD, Merrill AJ, Gerber L (1985) Clinical effects and side effects of Amrinone. A study of 24 patients with chronic congestive heart failure. Arch Intern Med 145: 825–829PubMedCrossRefGoogle Scholar
  19. 19.
    Sinoway LS, Maskin CS, Chadwick B, Forman B, Sonnenblick EH, Le Jemtel TH (1983) Longterm therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. JACC 2: 327–331PubMedGoogle Scholar
  20. 20.
    Slager CJ, Reiber JHC, Schuurbiers JCH, Meester GT (1978) Contouromat, a hard-wired left ventricular angio processing system. Design and application. Comput Biomed Res 11: 491–502PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • F. Piscione
    • 1
  • B. E. Jaski
  • P. W. Serruys
  1. 1.ThoraxcentreErasmus University RotterdamRotterdamThe Netherlands

Personalised recommendations